Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Reneo Pharmaceuticals (NASDAQ: RPHM) announced it will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation, scheduled for June 1 at 1:00 PM ET, will be in a fireside chat format. Reneo focuses on therapies for rare genetic mitochondrial diseases, developing REN001, which aims to enhance ATP production and mitochondrial function. This therapy shows promise in increasing gene transcription related to metabolism and fatty acid oxidation.

News Market Reaction – RPHM

+5.62%

+5.62% Session move

In the trading session that priced this news, RPHM gained 5.62%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will present and participate in one-on-one investor meetings at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.

Presentation details can be found below.

Date:	Tuesday, June 1, 2021
Time:	1:00 PM ET
Presentation Format:	Fireside chat

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com 

FAQ

What is Reneo Pharmaceuticals' involvement in the Jefferies Virtual Healthcare Conference 2021?

Reneo Pharmaceuticals will present and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference from June 1-4, 2021.

When will Reneo Pharmaceuticals present at the Jefferies Conference?

Reneo Pharmaceuticals' presentation is scheduled for June 1, 2021, at 1:00 PM ET.

What format will Reneo Pharmaceuticals' presentation take during the conference?

The presentation will be in a fireside chat format.

What is REN001 and what does it aim to treat?

REN001 is a therapy developed by Reneo Pharmaceuticals aimed at treating rare genetic mitochondrial diseases by enhancing ATP production and mitochondrial function.

What is the primary focus of Reneo Pharmaceuticals?

Reneo Pharmaceuticals focuses on developing therapies for patients with rare genetic mitochondrial diseases.